AllStripes provides an update on the inclusion body myositis (IBM) research program and the video includes a step-by-step walkthrough...
After Diagnosis: The Burden of Care and the Evolving Doctor/Patient Relationship
, , Featured, Video
Dr. Salman Bhai joins MSU to share best practices related to myositis care and empowers you to seek the...
Meet Dr. Bhai who is working together with MSU, collaborating on myositis patient-centered research, patient education, grants, and improving...
Manuel Lubinus, MBA, Ph.D. has been appointed to our newly created Scientific Advisory Board as Patient-Centric Research Advisor and...
Help researchers and clinicians better understand how patients with myositis and other autoimmune conditions feel about COVID-19/the novel coronavirus.
Introduction to the PRESIDIO Clinical Trial of KZR-616 for the Treatment of Polymyositis and Dermatomyositis
, , Featured, Video
Dr. Mary Katherine (MK) Farmer, MD, Rheumatologist and Senior Medical Director at Kezar Life Sciences, joined us live online...
Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis
, , Featured, Inclusion Body Myositis (IBM)
Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
Introduction to Ra Pharma & the Potential of Zilucoplan for the Treatment of IMNM Webinar
, , Featured, Video
Ben Matys, Sr. Clinical Trial Manager, and Ramin Farzaneh-Far, Chief Medical Officer of Ra Pharma, joined MSU) on November...
Myositis Support and Understanding (MSU) partners with the University of Pittsburgh for a new NIH-sponsored study entitled, “Myositis Patient...
The success of the Registry effort depends on the cooperative efforts of IBM patients around the world. The IBM...
Watch the AllStripes, formerly RDMD, video session we did in 2020 to learn more about the Inclusion Body Myositis...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis Video
, , Featured, Inclusion Body Myositis (IBM)
The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
The Performance of the EULAR/ACR IIM classification criteria in an expert-defined 10 year incident cohort
, , Featured, Myositis
This paper assesses the performance of EULAR/ACR classification criteria in a cohort of IIM cases and examines how subtypes...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM
, , Inclusion Body Myositis (IBM), Video
Watch "An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for sIBM" with Dr. Mazen Dimachkie,...
Learn about how clinical trials work in this educational and interactive video session led by Lindsey Wahlstrom-Edwards, Head of...
Identification of Predictors for Interstitial Lung Disease in Myositis Patients: A Systematic Review
, , Featured, Myositis, News
Interstitial lung disease (ILD) is a well-recognized complication in the spectrum of diseases known as the idiopathic inflammatory myopathies...
We are excited to announce a new collaboration with RDMD, a company that aims to jumpstart research for patients...
DETERMINE - a Phase 3 trial designed to evaluate the efficacy and safety of lenabasum for the treatment of adults...
The first step when approaching a patient with muscle weakness – Differential diagnosis of idiopathic inflammatory myopathies in adults
, , Featured, Myositis
Information on the differential diagnosis of adults with muscle weakness. Differential diagnosis is the process of distinguishing a specific...
Myositis and Cancer: Risk highest for carriers of anti-TIF1 antibody
, , Dermatomyositis, Featured, News
The research found that DM patients with the anti-transcriptional intermediary factor 1 (anti-TIF1) antibody were more than three times...
